Association calls for more biosimilar cancer therapies in Europe

11-10-2018

Cancer biosimilars are slow to enter European drugs markets even after the branded products have gone off-patent, according to the Association of European Cancer Leagues.


Association of European Cancer Leagues, biosimilars, patent, patent expiry, cancer

LSIPR